Table 3.
Method | MAPE | MAE | MSE | r | R2 |
---|---|---|---|---|---|
Ensemble approach |
18.36% (11.74%, 24.98%) |
4.70 (3.56, 5.84) |
34.53 (18.81, 50.25) |
0.84 | 0.71 |
DaTscan + MDS-UPDRS-III + Clinical Information |
19.89% (12.48%, 27.30%) |
5.04 (3.78, 6.29) |
40.41 (22.09, 58.74) |
0.81 | 0.66 |
DaTscan + MDS-UPDRS-III (No Clinical Information) |
19.89% (13.63%, 26.15%) |
5.22 (4.09, 6.35) |
39.37 (24.48, 54.25) |
0.81 | 0.66 |
MDS-UPDRS-III + Clinical (No DaTscan Information) |
26.33% (17.76%, 34.91%) |
6.63 (5.11, 8.14) |
65.85 (36.14, 95.57) |
0.64 | 0.41 |
DaTscan + Clinical (No MDS-UPDRS-III Information) |
35.48% (22.50%, 48.46%) |
9.15 (6.90, 11.39) |
131.71 (73.60, 189.81) |
0.04 (n.s.) |
0.00 |
Data in parentheses are 95% confidence intervals
MAPE, mean absolute percentage error; MAE, mean absolute error; MSE, mean squared error; n.s., not significant; r, Pearson correlation coefficient; R2, coefficient of determination. Unless indicated, values for r were significant (P < 0.001)